Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

Professor Park Joon-sik of obstetrics and gynecology at Soonchunhyang University Bucheon Hospital announced on the 14th that ...

Dose escalation offers no survival benefits but increases grade ≥ 3 toxicity compared with standard radiation in patients ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep.

During a live event, Richard F. Riedel, MD, discussed Desmoid Tumor Working Group and NCCN guidelines for treating patients ...

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.